

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/SE/2023-24/122 February 29, 2024

To, Listing/ Compliance Department **BSE LTD.** Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 To, Listing/ Compliance Department **National Stock Exchange of India Limited** "Exchange Plaza", Plot No C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051

NSE SYMBOL: AARTIDRUGS

BSE CODE: 524348

Sir/ Madam,

Sub:- Credit Rating Ref: Regulation 30 and 46(2)(r) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that ICRA Limited has reaffirmed credit rating on Long term- Fund based term loan, Long term- Fund based CC and Short term- Fund based/Non-fund based facilities of the Company.

The details of credit ratings are mentioned hereunder:

Instrument	Amount (Rs. Crore)	Rating Action
Long term- Fund based term loan	209.09	[ICRA] AA- (stable); Reaffirmed
Long term- Fund based CC	65.00	[ICRA] AA- (stable); Reaffirmed
Short term- Fund based/Non-fund based facilities	1,085.00	[ICRA] A1+; Reaffirmed
Total	1,359.09 (enhanced from 1,349.11 Crore)	

Copy of detailed rating rationale issued by ICRA Limited dated 28th February 2024 is enclosed herewith.

You are requested to take the same on records.

Thanking you,

Yours Faithfully, FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. NO.:- F12932



ICRA Limited

Ref: ICRA/ Aarti Drugs Limited/28022024/1

Date: February 28, 2024

Mr. Adhish Patil Chief Financial Officer

Aarti Drugs Limited Mahendra Industrial Estate, Ground Floor, Road No 29, Plot No 109-D, Sion (East), Mumbai- 400 022

Dear Sir,

Re: ICRA-assigned Credit Rating for Rs.1359.09 crore (enhanced from Rs. 1349.11 crore) Bank Facilities of Aarti Drugs Limited

Please refer the Rating Agreement/Statement of Work dated September 05, 2022, between ICRA Limited ("ICRA") and your company, whereby, ICRA is required to review the ratings assigned to your company on an annual basis or as and when the circumstances so warrant. Further, please refer Statement of work dated February 12, 2024, seeking an enhancement of the captioned limit(s) of Bank Facilities of your company from **Rs. 1349.11 crore** to **Rs. 1359.09 crore**.

Based on a review of the latest developments, the Rating Committee of ICRA, after due consideration has reaffirmed the long-term rating at **[ICRA]AA- (pronounced ICRA double A minus)** and the short-term rating at **[ICRA]A1+ (pronounced ICRA A one plus)** for the captioned Bank Facilities ("Rating") of **Rs.1349.11 crore** and has assigned a long-term rating of **[ICRA]AA- (pronounced ICRA double A minus)** and a short-term rating of **[ICRA]A1+ (pronounced ICRA]A4- (pronounced ICRA double A minus)** and a short-term rating of **[ICRA]A1+ (pronounced ICRA A one plus)** to the enhanced Bank Facilities of **Rs. 9.98 crore**. The outlook on the long-term rating is **Stable**. For Rating definition(s), please refer to ICRA website at <u>www.icra.in</u>.

In any of your publicity material or other document wherever you are using the above Rating(s), it should be stated as **[ICRA]AA-(Stable)/[ICRA]A1+.**

The aforesaid Rating(s) will be due for surveillance any time before **February 21, 2025**. However, ICRA reserves the right to review and/or, revise the above Rating(s) at any time on the basis of new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the Rating(s). Therefore, request the lenders and investors to visit ICRA website at <u>www.icra.in</u> for latest Rating(s) of the Company.

The Rating(s) are specific to the terms and conditions of the Bank Facilities as indicated to us by you, and any change in the terms or size of the same would require a review of the Rating(s) by us. In case there is

RATING • RESEARCH • INFORMATION



ICRA Limited

any change in the terms and conditions or the size of the rated Bank Facilities, the same must be brought to our notice before the Bank Facilities is used by you. In the event such changes occur after the Ratings have been assigned by us and their use has been confirmed by you, the Ratings would be subject to our review, following which there could be a change in the Ratings previously assigned. Notwithstanding the foregoing, any change in the over-all limit of the Bank Facilities from that specified in the first paragraph of this letter would constitute an enhancement that would not be covered by or under the said Rating Agreement.

ICRA reserves the right to review and/or, revise the above Rating(s) at any time on the basis of new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the Rating(s) assigned.

The Rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated Bank Facilities availed/issued by your Company.

The Rating(s) assigned to the Bank Facilities of your Company shall require revalidation if there is any change in the size or structure of the rated Bank Facilities.

You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the Company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded.

We look forward to your communication and assure you of our best services.

With kind regards, Yours sincerely, For ICRA Limited

SRI KUMAR KRISHNAMURTHY

Digitally signed by SRI KUMAR KRISHNAMURTHY Date: 2024.02.28 17:17:41 +05'30'

Srikumar Krishnamurthy

Senior Vice President & Co-Group Head | Corporate Ratings ksrikumar@icraindia.com



ICRA Limited

Annexure

Instrument Details

Details of Bank Limits Rated by ICRA (Rated on Long-Term Scale)	Amount (Rs. crore)	Rating	Rating Assigned on
Fund based Facilities	Term Loan		
Kotak Mahindra Bank Limited	150.00	[ICRA] AA- (stable)	February 22, 2024
The Shamrao Vithal Cooperative Bank	31.04		
HDFC Bank Limited	28.05		
Fund based Facilities	Cash Credit		
HDFC Bank Limited	64.00		
IDBI Bank Limited	1.00	1	
Total	274.09		

Details of Bank Limits Rated by ICRA (Rated on Short-Term Scale)	Amount (Rs. crore)	Rating	Rating Assigned on
Fund based/ Non-Fund based	Working Capital		
Facilities	Facilities		
HDFC Bank Limited	236.00		
Standard Chartered Bank	100.00		
Axis Bank Limited	225.00		
DBS Bank India Limited	55.00		
State Bank of India	75.00	[ICRA]A1+	February 22, 2024
Kotak Mahindra Bank Limited	180.00		
Union Bank of India	70.00		
HSBC Limited	100.00		
IDBI Bank Limited	44.00		
Total	1085.00		